RIL arm Strand pushes into genetic wellness testing
Raliance Industries LTD supported genomic company Strand Life Sciences director and General Manager Ramesh Hariharan this dream and intention this Mint.
At the beginning of this month, Strand launched Nutridna, a genetic test that helps modify your diet according to genetic make -up. It analyzes features such as vitamin metabolism, food sensitivities, weight management, fitness performance, inflammation and sleep patterns.
This is the first nutrition -based genetic test by Strand and the company is trying to expand the product basket for nutrition, intestinal and skin health.
Read more: Rahul Mattan: Indian genes can save the world from rare diseases
Hariharan, Nutridna test was better than any product initiated by the company in the past. Mint.
Priced La18,500 (with entry offer La12,500), the test is still expensive compared to a blood test or full body health control. La500 and La2,000.
However, these tests are a way to interact with a larger consumers and to comfort them with genomics, so that according to Hariharan, they may prefer more life -saving tests, such as early cancer detection.
Hariharan, “Our experiences, in general, the consumer, life and death before confronting questions about the less serious thing is to deal with things,” he said.
The genomic test includes other things, as well as analyzing or seizing a person’s DNA to identify or diagnose or diagnose or display for various cancers, rare diseases, genetic conditions, and neurological disorders.
In India, genomic test is largely used to diagnose rare diseases or to test the risk and recurrence factors of cancer.
Although Strand is still largely engaged in medical practitioners and prescribed tests, Reliance’s subsidiary expects a significant increase in direct tests for the consumer who starts 27 FY and FY28.
The Wellness -based preventive tests still constitute only part of Strand’s overall test. The company, tens of thousands of foreseeted tests per year, for hours, HARİHARAN Mint In a previous conversation.
For this year, Strand expects health tests to be hundreds of a month. Hariharan said that this would increase ten times in 27 financial years.
Hariharan, “… in 10 years, we see an overwhelming part of our income from the preventive and healthy living space,” he said.
A growing market
In addition to other genomic test players such as Medgenome and Mapmygenome in India, diagnostic players such as Metropolis Healthcare also offer a number of health genetic tests.
“Individuals, heart disease, heart disease, diabetes, cancer and other chronic diseases, based on genetic sensitivity, based on the deeper level of health risks go beyond annual controls,” he said. Mint.
Read more: Health Services for All: India may lead by shaping the future of artificial intelligence and biotechnology
Medgenome provides tests to improve long life through the detection of heart health, metabolic health, neurological health, cancer risk and platform Geneessense.
The metropolis, the largest diagnostic laboratory chain of India, has developed intravenous skills for genomic and offers two preventive tests for early cancer screening and cardiac health.
“There is a significant change in focusing on proactive health services from the reagent. Increasingly, individuals with health consciousness are looking for personalized information for lifestyle and chronic diseases such as diabetes, cardiovascular situations and some cancers.” Mint.
Purchase of Purchase
According to industrial estimates, the Indian Genomics test market is worth $ 593 million in 2023. This is expected to increase to 2 billion dollars by 2030.
An important factor that increases accessibility to genomic tests is a decrease in prices. In the last five years, prices fell by 50%. This means that a wider patient pool can access these tests, not only for rare and special diseases.
Costs for some tests still La1 Lakh and more, health -based tests are priced La10,000 – 20,000.
Companies are investigating partnerships with companies that offer health checks and digital health platforms to present them. Medgenome’s tests are available in TATA 1mg.
Strand is investigating partnerships with digital health platforms, corporate companies and fitness platforms.
However, healthcare professionals warn against the undisputed use of these tests. Molecular Hematology and Oncology Advisor in Fortis Hospital Gurgaon “I can excess on the Flip side, use Google or chatgpt to interpret, may lead to unnecessary stress or anxiety,” Shrinidhi Nathany said. Mint.
Companies such as Strand and Medgenome bind users to genetic experts – certified paramedal practitioners – who offer consultancy and help users to interpret the tests correctly.
Read more: Gene Editing: Is it ready to rewrite the book of human life?
